Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Astellas Appoints National Oncology Sales VP | Contract Pharma

What are you searching for?

Sign in

Astellas Appoints National Oncology Sales VP

Chelsea Glinski is recognized by the Healthcare Businesswomen's Association (HBA) as a 2019 Luminary

By: Cassandra Gervolino

Astellas has appointed Chelsea Glinski as national vice president, Oncology Sales, Astellas US. In this role, Glinski will oversee U.S. sales for the XTANDI brand, and contribute to the growth and development of the oncology sales organization overall.
 
Glinski previously served as executive director of Astellas’ market access and reimbursement strategy, where she led the design and operations of reimbursement services and patient support programs across the Astellas portfolio. In addition, Glinski held operational roles in Astellas’ Health Systems Business Unit. Recently, she was recognized by the Healthcare Businesswomen’s Association (HBA) as a 2019 Luminary.
 
“At Astellas, we strive to make every day better for those impacted by cancer,” said Mark Reisenauer, senior vice president, Oncology Business Unit. “Chelsea’s breadth of healthcare experience, with a career that started in research and expanded into strategy and operations, and most recently in overseeing patient support and access programs, makes her a natural fit to help Astellas’ oncology franchise continue to grow and evolve.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters